BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 10230457)

  • 1. [Second malignancies after the therapy of Hodgkin's disease: the Freiburg collective 1940 to 1991].
    Slanina J; Heinemann F; Henne K; Moog G; Frommhold H
    Strahlenther Onkol; 1999 Apr; 175(4):154-61. PubMed ID: 10230457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hodgkin's disease: study of treatment intensities and incidences of second malignancies.
    Rodriguez MA; Fuller LM; Zimmerman SO; Allen PK; Brown BW; Munsell MF; Hagemeister FB; McLaughlin P; Velasquez WS; Swan F
    Ann Oncol; 1993 Feb; 4(2):125-31. PubMed ID: 8448080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome.
    Mauch PM; Kalish LA; Marcus KC; Coleman CN; Shulman LN; Krill E; Come S; Silver B; Canellos GP; Tarbell NJ
    Blood; 1996 May; 87(9):3625-32. PubMed ID: 8611686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease.
    Beaty O; Hudson MM; Greenwald C; Luo X; Fang L; Wilimas JA; Thompson EI; Kun LE; Pratt CB
    J Clin Oncol; 1995 Mar; 13(3):603-9. PubMed ID: 7884422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second malignancies after Hodgkin's disease: the Munich experience.
    Munker R; Grützner S; Hiller E; Aydemir U; Enne W; Dietzfelbinger H; Busch M; Haas R; Emmerich B; Schmidt M; Dühmke E; Hölzel D; Wilmanns W
    Ann Hematol; 1999 Dec; 78(12):544-54. PubMed ID: 10647878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of second cancers in patients treated for Hodgkin's disease.
    Boivin JF; Hutchison GB; Zauber AG; Bernstein L; Davis FG; Michel RP; Zanke B; Tan CT; Fuller LM; Mauch P
    J Natl Cancer Inst; 1995 May; 87(10):732-41. PubMed ID: 7563150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment.
    Swerdlow AJ; Barber JA; Hudson GV; Cunningham D; Gupta RK; Hancock BW; Horwich A; Lister TA; Linch DC
    J Clin Oncol; 2000 Feb; 18(3):498-509. PubMed ID: 10653865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy.
    Chronowski GM; Wilder RB; Tucker SL; Ha CS; Younes A; Fayad L; Rodriguez MA; Hagemeister FB; Barista I; Cabanillas F; Cox JD
    Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):36-43. PubMed ID: 12504034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second cancer among long-term survivors from Hodgkin's disease.
    Nyandoto P; Muhonen T; Joensuu H
    Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):373-8. PubMed ID: 9788418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of second solid cancer in patients after treatment of Hodgkin's disease.
    Glanzmann C; Veraguth A; Lütolf UM
    Strahlenther Onkol; 1994 Mar; 170(3):140-6. PubMed ID: 8160093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second solid malignancies after combined modality therapy for Hodgkin's disease.
    Doria R; Holford T; Farber LR; Prosnitz LR; Cooper DL
    J Clin Oncol; 1995 Aug; 13(8):2016-22. PubMed ID: 7636543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study.
    Swerdlow AJ; Higgins CD; Smith P; Cunningham D; Hancock BW; Horwich A; Hoskin PJ; Lister TA; Radford JA; Rohatiner AZ; Linch DC
    J Clin Oncol; 2011 Nov; 29(31):4096-104. PubMed ID: 21969511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation.
    Salloum E; Doria R; Schubert W; Zelterman D; Holford T; Roberts KB; Farber LR; Kiehl RK; Cardinale J; Cooper DL
    J Clin Oncol; 1996 Sep; 14(9):2435-43. PubMed ID: 8823321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time.
    Foss Abrahamsen A; Andersen A; Nome O; Jacobsen AB; Holte H; Foss Abrahamsen J; Kvaløy S
    Ann Oncol; 2002 Nov; 13(11):1786-91. PubMed ID: 12419752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased risk of second cancers in managing Hodgkins disease: the 20-year Leiden experience.
    Sont JK; van Stiphout WA; Noordijk EM; Molenaar J; Zwetsloot-Schonk JH; Willemze R; Vandenbroucke JP
    Ann Hematol; 1992 Nov; 65(5):213-8. PubMed ID: 1457578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
    Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
    J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: patterns of failure, late toxicity and second malignancies.
    Vlachaki MT; Ha CS; Hagemeister FB; Fuller LM; Rodriguez MA; Besa PC; Hess MA; Brown B; Cabanillas F; Cox JD
    Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):609-16. PubMed ID: 9336140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
    Engert A; Plütschow A; Eich HT; Lohri A; Dörken B; Borchmann P; Berger B; Greil R; Willborn KC; Wilhelm M; Debus J; Eble MJ; Sökler M; Ho A; Rank A; Ganser A; Trümper L; Bokemeyer C; Kirchner H; Schubert J; Král Z; Fuchs M; Müller-Hermelink HK; Müller RP; Diehl V
    N Engl J Med; 2010 Aug; 363(7):640-52. PubMed ID: 20818855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
    Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
    Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.